Drug intelligence / Profile preview

Climaxan

Development stage: Unknown
Lead developer: Materia Medica Holding
Administration: Oral, Sublingual

Overview

Climaxan is a non-hormonal, multi-component homeopathic medicine developed by Materia Medica Lifesciences for the symptomatic relief of menopausal disorders in women. It is formulated as a combination of three active homeopathic ingredients: Cimicifuga racemosa (black cohosh), Lachesis mutus (bushmaster snake venom), and Apis mellifica (honeybee venom). Climaxan is indicated to alleviate common manifestations of menopausal syndrome, including irritability, emotional lability, sleep disturbances, headaches, dizziness, palpitations, sweating, and hot flashes. It is administered orally as sublingual tablets or granules.

Brand names: ClimaxanKlimaksan
Other names: Climaxan homeopathicKlimaksan homeopathic

Beyond the preview

Go deeper on Climaxan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Climaxan.

Explore the full profile